HSBC raised the firm’s price target on Novartis (NVS) to CHF 95 from CHF 89 and keeps a Reduce rating on the shares. The firm says the uncertain macro backdrop, rising geopolitical risk, and lower exposure to AI disruption risks could attract investors to healthcare and drive outperformance in the coming quarter.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- District court rules federal limits to vaccines not based on science, NYT says
- Novartis receives FDA approval for Cosentyx for patients aged 12 and older
- Relay Therapeutics price target raised to $22 from $15 at Guggenheim
- Largest borrow rate increases among liquid names
- Argus upgrades Novartis to Buy after pullback in shares